|
A study on reducing urinary protein by astaxanthin in patients with IgA nephropathy
2015, 14 (12):
718-722.
doi: 10.3969/j.issn.1671-4091.2015.12.005
【Abstract】Objective The aim of the current study was to investigate whether astaxanthin could reduce urinary protein excretion in patients with IgA nephropathy. Methods This was a self- controlled study. Patients diagnosed with IgA nephropathy and treated in our hospital in the period between Dec. 2014 and Jun. 2015 were recruited. They had stable urinary protein excretion for at least 3 months, stable renal function and steady doses of antihypertensives. Seventeen patients met the criteria and were willing to accept astaxanthin treatment, and 16 (45.4±13.4 years, 7 males and 9 females) of them completed the study. All patients received oral astaxanthin 1~2 tablets each time, twice daily for 3 month. 24h urinary protein (24hUP), serum albumin (Alb), creatinine (Scr), estimated glomerular filtration rate (eGFR), total cholesterol (TChol), high density lipoprotein (HDL), low density lipoprotein (LDL) and triglyceride (TG) were measured before taking astaxanthin and re-examined after the treatment once a month for 3 months. Normally distributed data (TChol, HDL and LDL) were analyzed using one- way analysis of variance (ANOVA). Non- normally distributed data (24hUP, Alb, Scr, eGFR and TG) were analyzed using Friedman non-parametric test. Wilcoxon rank sum test was used for pairwise comparison. Jonckheere-Terpstra was used for trend analysis. Results At baselines, 24hUP, Alb, Scr, TChol, eGFR, HDL, LDL and TG was 2.65 (1.43, 5.02) g/d, 41.0 (37.6, 44.2) g/L, 135.0 (95.0, 224.0) μmol/L, 47.81 (32.91, 65.39) ml/min.1.73m2, 5.83±1.43 mmol/L, 1.29±0.37 mmol/L, 3.20±0.86 mmol/L and 1.26 (1.03,3.78) mmol/L, respectively, and changed to 1.35 (0.86,2.96) g/d, 42.3 (40.5,42.7) g/L,
154.0 (70.0,192.0) μmol/L, 41.49 (32.50,100.51) ml/min.1.73m2, 5.32 ± 1.12 mmol/L, 1.12 ± 0.32 mmol/L, 3.28±0.82 mmol/L and 1.49 (1.04,2.75) mmol/L, respectively, after the treatment for 3 months. After astaxanthin treatment, 24hUP and eGFR had a significantly downward trend (P<0.001), Scr had a significantly up- ward trend (P<0.001), but change trends of Alb, TChol, HDL, LDL and TG were not found. Conclusions These results suggested that urinary protein excretion could be reduced by adding astaxanthin to traditional treatment in patients with IgA nephropathy.
Metrics
|